Format
Items per page
Sort by

Send to:

Choose Destination

Results: 15

Cited In for PubMed (Select 22674883)

1.

Giant cell arteritis: Current treatment and management.

Ponte C, Rodrigues AF, O'Neill L, Luqmani RA.

World J Clin Cases. 2015 Jun 16;3(6):484-94. doi: 10.12998/wjcc.v3.i6.484. Review.

2.

Linking classification and therapeutic management of vasculitides.

Baldwin C, Carette S, Pagnoux C.

Arthritis Res Ther. 2015 Jun 2;17:138. doi: 10.1186/s13075-015-0654-x.

3.

Takayasu arteritis in childhood: retrospective experience from a tertiary referral centre in the United Kingdom.

Eleftheriou D, Varnier G, Dolezalova P, McMahon AM, Al-Obaidi M, Brogan PA.

Arthritis Res Ther. 2015 Feb 25;17:36. doi: 10.1186/s13075-015-0545-1.

4.

The role of biological agents in the management of large vessel vasculitis (LVV): a systematic review and meta-analysis.

Osman M, Pagnoux C, Dryden DM, Storie D, Yacyshyn E.

PLoS One. 2014 Dec 17;9(12):e115026. doi: 10.1371/journal.pone.0115026. eCollection 2014.

5.

State of the art in the treatment of systemic vasculitides.

Luqmani RA.

Front Immunol. 2014 Oct 13;5:471. doi: 10.3389/fimmu.2014.00471. eCollection 2014. Review.

6.

Anti-cytokine treatment for Takayasu arteritis: State of the art.

Tombetti E, Di Chio MC, Sartorelli S, Bozzolo E, Sabbadini MG, Manfredi AA, Baldissera E.

Intractable Rare Dis Res. 2014 Feb;3(1):29-33. doi: 10.5582/irdr.3.29.

7.

The role of 18F-FDG PET/CT in large-vessel vasculitis: appropriateness of current classification criteria?

Balink H, Bennink RJ, van Eck-Smit BL, Verberne HJ.

Biomed Res Int. 2014;2014:687608. doi: 10.1155/2014/687608. Epub 2014 Aug 14. Review.

8.

Clinical practice. Giant-cell arteritis and polymyalgia rheumatica.

Weyand CM, Goronzy JJ.

N Engl J Med. 2014 Jul 3;371(1):50-7. doi: 10.1056/NEJMcp1214825. Review. No abstract available.

9.

Advances and challenges in the diagnosis and treatment of polymyalgia rheumatica.

Kermani TA, Warrington KJ.

Ther Adv Musculoskelet Dis. 2014 Feb;6(1):8-19. doi: 10.1177/1759720X13512450. Review.

10.

Immune mechanisms in medium and large-vessel vasculitis.

Weyand CM, Goronzy JJ.

Nat Rev Rheumatol. 2013 Dec;9(12):731-40. doi: 10.1038/nrrheum.2013.161. Epub 2013 Nov 5. Review.

11.

Refractory PMR with aortitis: life-saving treatment with anti-IL6 monoclonal antibody (tocilizumab) and surgical reconstruction of the ascending aorta.

Ashraf FA, Anjum S, Hussaini A, Fraser A.

BMJ Case Rep. 2013 Jun 18;2013. pii: bcr2013009523. doi: 10.1136/bcr-2013-009523.

12.

Design of the tocilizumab in giant cell arteritis trial.

Unizony SH, Dasgupta B, Fisheleva E, Rowell L, Schett G, Spiera R, Zwerina J, Harari O, Stone JH.

Int J Rheumatol. 2013;2013:912562. doi: 10.1155/2013/912562. Epub 2013 Apr 7.

13.

Headache attributed to cranial or cervical vascular disorders.

Kapoor S.

Curr Pain Headache Rep. 2013 May;17(5):334. doi: 10.1007/s11916-013-0334-y. Review.

14.

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.

Smolen JS, Schoels MM, Nishimoto N, Breedveld FC, Burmester GR, Dougados M, Emery P, Ferraccioli G, Gabay C, Gibofsky A, Gomez-Reino JJ, Jones G, Kvien TK, Murakami M, Betteridge N, Bingham CO 3rd, Bykerk V, Choy EH, Combe B, Cutolo M, Graninger W, Lanas A, Martin-Mola E, Montecucco C, Ostergaard M, Pavelka K, Rubbert-Roth A, Sattar N, Scholte-Voshaar M, Tanaka Y, Trauner M, Valentini G, Winthrop KL, de Wit M, van der Heijde D.

Ann Rheum Dis. 2013 Apr;72(4):482-92. doi: 10.1136/annrheumdis-2012-202469. Epub 2012 Nov 21.

15.

Clinical use of biologics in vasculitis syndromes.

Paroli M.

Biologics. 2012;6:371-8. doi: 10.2147/BTT.S37537. Epub 2012 Oct 25.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk